Leveraging the Power of Targeted Radiotherapy to Build a Pipeline of Highly Differentiated Radiotherapeutics for Conditioning, Heme and Solid Tumor Malignancies

Time: 12:00 pm
day: Day One


  • Leading specialty oncology radiotherapeutics company with a Ph III-complete, paradigm shifting induction and conditioning agent, Iomab-B for R/R AML and a robust pipeline of both heme and solid tumor opportunities leveraging a 160-patent backed proprietary platform
  • Actimab-A investigated in R/R AML trials including in combination with Bcl- 2 targeted venetoclax and the salvage chemotherapy CLAG-M, the latter demonstrating 80% ORR
  • Strong R&D platform pioneering targeted radiotherapies in solid tumors, bolstered by partnerships with Astellas Pharma, Inc. for solid tumor theranostics, AVEO Oncology for a first-in-class Actinium-225 HER3 targeting radiotherapy, and EpicentRx, Inc. for combinations with their clinical stage CD47-SIRPα inhibitor